Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders
Double Blind Placebo Controlled Trial of Anticonvulsant Effects of n-3 PUFAs in Human Subjects With Epilepsy
Sponsor: North York General Hospital
Terminated
Unable to recruit participants
A PHASE2/PHASE3 clinical study on Epilepsy (Treatment Refractory), this trial is terminated or withdrawn. The trial is conducted by North York General Hospital and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Unknown Status → Terminated
-
Jan 2021 — Mar 2023 [monthly]
Unknown Status PHASE2_PHASE3
▶ Show 4 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- North York General Hospital
- Ontario Brain Institute
- The Canadian College of Naturopathic Medicine
- University Health Network, Toronto
For direct contact, visit the study record on ClinicalTrials.gov .